Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Rider Michael JOwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-81Price:$180.00
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Rider Michael JOwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-200Price:$173.25
-
Feb 22, 2024 (filed on Feb 23, 2024)Insider Name:Farrell Peter COwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,935Price:$182.66
-
Nov 27, 2023 (filed on Nov 29, 2023)Insider Name:Sandercock BrettOwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,000Price:$152.62
-
Nov 22, 2023 (filed on Nov 27, 2023)Insider Name:Rider Michael JOwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-72Price:--
-
Nov 20, 2023 (filed on Nov 20, 2023)Insider Name:Farrell Michael J.Ownership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,353Price:$148.94
-
Nov 20, 2023 (filed on Nov 20, 2023)Insider Name:Douglas Robert AndrewOwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,375Price:$148.94
-
Nov 20, 2023 (filed on Nov 20, 2023)Insider Name:Ghoshal KaushikOwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-367Price:$148.94
-
Nov 20, 2023 (filed on Nov 20, 2023)Insider Name:Farrell Michael J.Ownership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,353Price:$148.94
-
Nov 16, 2023 (filed on Nov 21, 2023)Insider Name:Burt CarolOwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,768Price:--
Filings by filing date
-
Mar 04, 2024 (filed on Mar 06, 2024)Insider Name:Rider Michael JOwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-81Price:$180.00
-
Mar 01, 2024 (filed on Mar 04, 2024)Insider Name:Rider Michael JOwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-200Price:$173.25
-
Feb 22, 2024 (filed on Feb 23, 2024)Insider Name:Farrell Peter COwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,935Price:$182.66
-
May 03, 2023 (filed on Feb 23, 2024)Insider Name:Farrell Peter COwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-12,600Price:$237.17
-
Nov 27, 2023 (filed on Nov 29, 2023)Insider Name:Sandercock BrettOwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,000Price:$152.62
-
Nov 22, 2023 (filed on Nov 27, 2023)Insider Name:Rider Michael JOwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-72Price:--
-
Nov 16, 2023 (filed on Nov 21, 2023)Insider Name:Burt CarolOwnership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,768Price:--
-
Nov 16, 2023 (filed on Nov 20, 2023)Insider Name:Farrell Michael J.Ownership Type:Direct OwnershipSecurities:ResMed Common Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:55,468Price:$148.90
-
Nov 16, 2023 (filed on Nov 20, 2023)Insider Name:Farrell Michael J.Ownership Type:Direct OwnershipSecurities:ResMed Common Stock OptionsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,462Price:--
-
Nov 20, 2023 (filed on Nov 20, 2023)Insider Name:Farrell Michael J.Ownership Type:Direct OwnershipSecurities:ResMed Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,353Price:$148.94
News
Biz Brief
Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9001 Spectrum Center Blvd SAN DIEGO CA 92123-1438 |
Tel: | N/A |
Website: | https://www.resmed.com |
IR: | See website |
Key People | ||
Michael J. Farrell Chairman of the Board, Chief Executive Officer | Jim Ellis Chief Commercial Officer | Brett A. Sandercock Chief Financial Officer |
Vered Keisar Chief People Officer | Lucile Blaise Senior Vice President - Strategy & Business Development | Urvashi Tyagi Chief Technology Officer |
Todd Friedman Chief Information Security Officer | Katrin Pucknat Chief Marketing Officer | Michael Rider General Counsel, Company Secretary, Chief Legal Officer | Amy Wakeham Chief Investor Relations Officer |
Business Overview |
ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. The Company's segments include Sleep and Respiratory Care and Software as a Service. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital software health applications, along with its devices, are designed to provide connected care to improve patient outcomes. Its portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, and cloud-based software and informatics solutions. Its comprehensive out-of-hospital software platforms support the professionals and caregivers. |
Financial Overview |
For the six months ended 31 December 2023, Resmed Inc revenues increased 14% to $2.27B. Net income decreased 2% to $428.2M. Revenues reflect Sleep and Respiratory Care segment increase of 12% to $1.98B, Software as a Service segment increase of 28% to $284.2M. Net income was offset by Selling, general and administrative increase of 10% to $445M (expense), Research and development increase of 12% to $149.6M (expense). |
Employees: | 10,140 as of Jun 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $28,113M as of Dec 31, 2023 |
Annual revenue (TTM): | $4,504M as of Dec 31, 2023 |
EBITDA (TTM): | $1,397M as of Dec 31, 2023 |
Net annual income (TTM): | $890.39M as of Dec 31, 2023 |
Free cash flow (TTM): | $673.11M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $1,016M as of Dec 31, 2023 |
Shares outstanding: | 147,088,888 as of Jan 22, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |